IFF third quarter
This article was originally published in The Rose Sheet
Executive SummaryFueled by growth in North America and Europe, worldwide fragrance sales increased 5% in dollars during the third quarter on pro forma basis, fragrance and flavor supplier announces in 1Oct. 24 release. North American fragrance sales grew 2%, as fine perfumery and aromachemicals each increased in "high single-digits." European fragrance sales up 8% in local currency, with 25% local currency fine fragrances gain based on new wins and pick-up in travel retail. Global flavor sales rose 5% in the quarter, contributing to 5% consolidated sales increase to $462.8 mil. versus comparable 2001 results. Net income up 18% to $49.6 mil., excluding nonrecurring charges. Integration of Bush Boake Allen completed during the quarter, IFF announces, providing savings "run rate" of $80 mil., ahead of plan. Firm projects Q4 consolidated dollar sales to increase in low single-digits, earnings per share to rise 8%-12%, excluding charges...
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.